Dr Reddy’s Labs unveils Sorafenib Tablets in US

Hyderabad: Pharma major, Dr. Reddy’s Laboratories Ltd., today announced the launch of the company’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of
Nexavar (sorafenib) Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration
(USFDA).

Sorafenib is a kinase inhibitor indicated for the treatment of 

. Unresectable hepatocellular carcinoma

. Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.

“We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable
generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr.
Reddy’s Laboratories Inc.


Dr. Reddy’s Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.

Nexavar is a trademark of Bayer HealthCare Pharmaceuticals Inc.

Read also: Dr Reddys arm, Olema Pharma ink pact to develop novel cancer therapies

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy’s operates in markets across the globe. The company’s major markets include – USA, India, Russia & CIS countries, and Europe.

Read also: Dr Reddys to sell Finast, Styptovit-E and 2 other brands to Torrent Pharma

Leave a Reply

Your email address will not be published.